|
Field
Planned Number of Observations
|
Before
We aim to enroll approximately 3,500 – 4,500 diabetics and pre-diabetics. We will continue enrollment in this range as our funding allows.
|
After
We aim to enroll approximately 4,000 diabetics, pre-diabetics, hypertensives, and prehypertensives in Experiment 1.
We aim to enroll approximately 750 diabetics, pre-diabetics, hypertensives, and prehypertensives in the "Baseline Choice" group added in Experiment 2 and continuing into Experiment 3.
We aim to enroll approximately 3-4,000 diabetics, pre-diabetics, hypertensives, and prehypertensives in Experiment 3.
We will continue enrollment in Experiment 3 as our funding allows.
|
|
Field
Sample size (or number of clusters) by treatment arms
|
Before
The following treatment group distribution is approximate, since enrollees will be assigned to treatments according to baseline strata in a pre-determined order, and some may withdraw following randomization but prior to the intervention.
Incentive Groups:
T1 – Random, 10,000 step target: 15%
T2 – Random, 12,000 step target: 25%
T3 – Random, 14,000 step target: 15%
T4 – Choice 1: 25%
T5 – Choice 2: 0.5%
T6 – Targeting: 17.5%
Non-incentive Group:
Monitoring Only: 2%
Information Treatment:
50% of the experimental sample excluding the Targeting group will be cross-randomized into the Information treatment prior to deciding which contract they prefer in Choice Menu 1.
|
After
The following treatment group distribution is approximate, since enrollees will be assigned to treatments according to baseline strata in a pre-determined order, and some may withdraw following randomization but prior to the intervention.
Experiment 1:
Incentive Groups:
T1 – Random, 10,000 step target: 15%
T2 – Random, 12,000 step target: 25%
T3 – Random, 14,000 step target: 15%
T4 – Choice 1: 25%
T5 – Choice 2: 0.5%
T6 – Targeting: 17.5%
Non-incentive Group:
Monitoring Only: 2%
Information Treatment:
50% of the experimental sample excluding the Targeting group will be cross-randomized into the Information treatment prior to deciding which contract they prefer in Choice Menu 1.
Experiment 2:
20% Baseline Choice
80% Allocated to Experiment 1 (no change to those within Experiment 1)
Experiment 3:
Incentive Groups:
T1 – Random, 10,000 step target: 9.3%
T2 – Random, 12,000 step target: 9.3%
T3 – Random, 14,000 step target: 9.3%
T4 – Choice 1: 19%
T5 – Choice 2: 0.5%
T8 – Choice 3: 19%
T6 – Targeting: 10%
T7 – Baseline Choice: 19%
Non-incentive Group:
Monitoring Only: 4.25%
Phase-in period duration cross-randomization:
50% of the experimental sample will be cross-randomized into a 13-day (rather than 6-day) phase-in period.
|